Table 5.
Peptide | |||
---|---|---|---|
0.5 mg | 1.0 mg | 2.0 mg | |
(n = 6) | (n = 6) | (n = 6) | |
Injection times of peptide† | 8 (4–12) | 8 (5–11) | 8 (4–34) |
Clinical outcome | |||
Antitumor effect | |||
PR/SD/PD | 0/4/2 | 0/4/2 | 1/3/2 |
Progression‐free survival (days)† | 102 (28–148) | 135 (60–675) | 131 (31–589) |
Overall survival (days)† | 233 (102–334) | 207 (135–675) | 344 (109–614) |
†Median (range). PD, progressive disease; PR, partial response; SD, stable disease.